Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|5|529-539

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.5, 2015-09, pp. : 529-539

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

By Wan George J.   Kozma Chris M.   Slaton Terra L.   Olson William H.   Feagan Brian G.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 384-393

Informa Healthcare

Access to resources Recommend Favorite

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 11, 2015-11 ,pp. : 1591-1595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 939-940

John Wiley & Sons Inc

Access to resources Recommend Favorite